The $400bn megadeal brewing in big pharma
Summary
AstraZeneca is in talks to acquire Bristol Myers Squibb in a deal valued at about $400bn. The combination would create the world's fourth-largest drugmaker by market value.
The talks signal that scale is again becoming a strategic priority in big pharma, as
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A merger would redraw the global pharma landscape and put pressure on rivals to respond with deals of their own.